Los Angeles Capital Management
DTIL icon

Los Angeles Capital Management’s Precision BioSciences DTIL Stock Holding History

Los Angeles Capital Management’s Portfolio DTIL Stock Details DTIL Fund Activity
Bought
Maintained
Sold
Quarter Market Value Status Shares Change in
Stake 		Trade Value Portfolio Weight Portfolio Position
2022
Q2 		– Sell
-5,793
Closed -$535K – 1357
2022
Q1 		$535K Buy
5,793
+4,083
+239% +$555K ﹤0.01% 1004
2021
Q4 		$380K Sell
1,710
-116
-6% -$32.4K ﹤0.01% 1135
2021
Q3 		$632K Sell
1,826
-81
-4% -$27.4K ﹤0.01% 950
2021
Q2 		$716K Sell
1,907
-352
-16% -$106K ﹤0.01% 1006
2021
Q1 		$702K Sell
2,259
-486
-18% -$170K ﹤0.01% 1069
2020
Q4 		$687K Buy
2,745
+879
+47% +$215K ﹤0.01% 1082
2020
Q3 		$345K Buy
1,866
+200
+12% +$39.8K ﹤0.01% 1220
2020
Q2 		$416K Buy
1,666
+866
+108% +$190K ﹤0.01% 1182
2020
Q1 		$145K Buy
+800
New +$209K ﹤0.01% 1245

Other funds holding DTIL

Capital World Investors
Capital World Investors Los Angeles, California $733B AUM 35.63% 1-Year Est. Return
GPP
Great Point Partners Greenwich, Connecticut $435M AUM 318.81% 1-Year Est. Return
EC
EcoR1 Capital San Francisco, California $2.36B AUM 204.53% 1-Year Est. Return
CH
CVI Holdings Wilmington, Delaware $116M AUM 5.68% 1-Year Est. Return
Vanguard Group
Vanguard Group Malvern, Pennsylvania $6.9T AUM 27.45% 1-Year Est. Return
CA
CHI Advisors New York $252M AUM 56.99% 1-Year Est. Return
RCMNY
Rubric Capital Management (New York) New York $9.44B AUM 68.42% 1-Year Est. Return
Marshall Wace
Marshall Wace London, United Kingdom $100B AUM 35.1% 1-Year Est. Return
BlackRock
BlackRock New York $5.72T AUM 30.48% 1-Year Est. Return
Acadian Asset Management
Acadian Asset Management Boston, Massachusetts $70.5B AUM 36% 1-Year Est. Return

Los Angeles Capital Management's DTIL Position: Q2 2022 in Review

Los Angeles Capital Management sold out of Precision BioSciences (DTIL) in Q2 2022, closing a stake of 5,793 shares — an estimated $535K sold.

Los Angeles Capital Management first reported a position in DTIL in Q1 2020 and held it in 9 quarters. The position peaked at $716K in Q2 2021. 119 funds tracked by Wall St. Rank hold DTIL as of Q2 2022.

  • Los Angeles Capital Management reported no remaining Precision BioSciences position as of Q2 2022 after selling out during the quarter.
  • Los Angeles Capital Management sold 5,793 Precision BioSciences shares in Q2 2022, an estimated $535K.
  • Los Angeles Capital Management first reported a position in Precision BioSciences in Q1 2020 and held it in 9 quarters.
  • Los Angeles Capital Management's Precision BioSciences position peaked at $716K in Q2 2021.
  • 119 funds tracked by Wall St. Rank held Precision BioSciences as of Q2 2022.

Based on Los Angeles Capital Management's 13F filing for Q2 2022, filed 5 Aug 2022.